Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 May 2012 (European Medicines Agency, 25 May 2012)

29 May 2012

The European Medicines Agency has released a list of opinions adopted at the May 2012 meeting of the Committee for Medicinal Products for Human Use (CHMP), including positive opinions on linagliptin combination with metformin for adults with type II diabetes, and a variation to the terms of the marketing authorisation for strontium ranelate to include the treatment of osteoporosis in men at increased risk of fracture.

Full list

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 May 2012 (European Medicines Agency, 25 May 2012)

Share this story

Top stories

Most read